# COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

> **NCT02253420** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 51 (actual)

## Conditions studied

- Medical Oncology

## Interventions

- **DRUG:** Copanlisib (BAY80-6946)
- **DRUG:** Itraconazole
- **DRUG:** Rifampin
- **DRUG:** Copanlisib (BAY80-6946)

## Key facts

- **NCT ID:** NCT02253420
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-08
- **Primary completion:** 2018-03-12
- **Final completion:** 2019-08-13
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253420, "COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02253420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*